NCT01440673

Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Gachon University Gil Medical Center · Academic / Other
• Sex: Female
• Age: 21 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

* Gynecological surgery is associated with a high incidence of postoperative nausea and vomiting. * NK1 receptor antagonists such as aprepitant appear to be highly effective for treating acute and delayed emesis, and yet understanding of the efficacy of different doses of aprepitant is limited. * We performed a prospective, randomized, double-blinded placebo-controlled study of 123 female adults scheduled for laparoscopic hysterectomy who received 80 mg aprepitant, 125 mg aprepitant, or a placebo.

Detailed description

123 female patients (ages 21-60) undergoing laparoscopic hysterectomy 1. 80mg aprepitant 2. 125mg aprepitant 3. placebo Incidences of nausea, vomiting/retching, and use of rescue antiemetics were recorded at 0, 1, 2, 24, and 48 h after surgery.

Conditions

• Postoperative Nausea and Vomiting

Interventions

Type	Name	Description
DRUG	Aprepitant	Aprepitant 80 mg, Aprepitant 125 mg

Timeline

• Start date: 2010-03-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2011-09-26
• Last updated: 2011-09-26

Locations

1 site across 1 country: South Korea